Discover
SRZN
Surrozen, Inc.
25.52
2 x 18.47
2 x 32.40
bid
ask
-
0.43
1.66%
2 @ 04:00 PM
25.52 +0.00 (0.00%)
| Ytd | 12.92% | |
| 1y | 189.67% |
24.50
day range
26.20
8.00
52 week range
35.00
| Open | 26.08 | Prev Close | 25.95 | Low | 24.50 | High | 26.20 | Mkt Cap | 296.30M |
| Vol | 91.66K | Avg Vol | 130.86K | EPS | -36.59 | P/E | N/A | Forward P/E | -2.75 |
| Beta | 0.94 | Short Ratio | 0.97 | Inst. Own | 77.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-09 | 50-d Avg | 27.00 | 200-d Avg | 21.85 | 1yr Est | 33.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -2.77 | -0.44 | 2.33 | 84.12% |
| 2024-08-12 | 2024-06 | -2.79 | N/A | N/A | N/A |
| 2024-08-12 | 2024-06 | -2.79 | -1.54 | 1.25 | 44.80% |
| 2024-05-08 | 2024-03 | -4.25 | -4.24 | 0.01 | 0.24% |
| 2024-05-08 | 2024-03 | -4.25 | N/A | N/A | N/A |
| 2024-04-03 | 2023-12 | -4.35 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-04-03 | COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-04-03 | KUTZKEY TIM PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-06-13 | LI YANG | Officer | 10.89K | Stock Award(Grant) |
| 2024-06-13 | PARKER CRAIG C | Chief Executive Officer | 5.82K | Stock Award(Grant) |
| 2024-06-13 | WILLIAMS CHARLES O | Chief Operating Officer | 5.86K | Stock Award(Grant) |
| 2023-06-14 | YEH WEN-CHEN M.D., PH.D. | Officer | 27.22K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Column Group LLC | 810.09K | 9.91M | 24.93% |
| 2024-09-29 | RA Capital Management, L.P. | 282.58K | 3.46M | 8.70% |
| 2024-09-29 | Nantahala Capital Management, LLC | 187.21K | 2.29M | 5.76% |
| 2024-09-29 | Stempoint Capital LP | 182.92K | 2.24M | 5.63% |
| 2024-09-29 | Armistice Capital, LLC | 139.00K | 1.70M | 4.28% |
| 2024-09-29 | Stonepine Capital Management, LLC | 110.00K | 1.35M | 3.38% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 46.58K | 569.65K | 1.43% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 18.13K | 221.69K | 0.56% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 10.98K | 134.32K | 0.34% |
| 2024-10-30 | iShares Micro Cap ETF | 5.27K | 64.44K | 0.16% |
| 2024-10-30 | Fidelity Total Market Index Fund | 2.75K | 33.57K | 0.08% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.59K | 31.70K | 0.08% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2023-12-14 |